Alteplase

Generic Name: Alteplase

Brand Names: Activase, Cathflo, Cathflo Activase

Drug Type: Biotech

Chemical Formula: -

CAS Number: 105857-23-6

Unique Ingredient Identifier: 1RXS4UE564

Background: Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. Alteplase is a purified gl...

Indication: Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and...

Associated Conditions: Acute Ischemic Stroke, Cardiac mortality, Heart Failure, Pulmonary Embolism Acute Massive, Central venous access device thrombosis

Associated Therapies: -

Clinical Trials

Current understanding of stroke and stroke mimics in adolescents and young adults

Articles discuss ischemic stroke in young adults, risk factors, mimics, and management, including global perspectives, pediatric stroke, and cerebrovascular complications of sickle cell disease.

medicalnewstoday.com

3 months ago

TNK stroke treatment: How it works, administration, and more

Tenecteplase (TNK) is a thrombolytic drug that may break down blood clots after a stroke, though not yet FDA-approved. It is administered as a single intravenous dose, targeting blood clots more effectively than alteplase, with a longer active duration and potentially lower cost. Risks include bleeding and thromboembolism. Ongoing trials aim to confirm its efficacy and safety for stroke treatment.

pharmaceuticalmanufacturer.media

3 months ago

Thrombolytic Science Receives FDA Investigational New Drug Clearance

Thrombolytic Science (TSI) received FDA approval for its Investigational New Drug application for mproUK, a recombinant fibrinolytic pro-enzyme, confirming its safety and tolerability. TSI's CEO highlights the potential of mproUK to transform treatment for thrombotic conditions, offering a faster, safer, and more effective reperfusion option. The drug's mechanism involves initiating clot lysis with tPA and completing it with prourokinase, akin to a car's starter and engine, respectively.

krgv.com

3 months ago

Medical Breakthrough: New drug being tested to help treat strokes

Two stroke types exist; one drug treats Ischemic strokes, another is tested for brain bleeds. Neurologist Joseph Broderick leads a global study on Recombinant Factor 7A to stop brain bleeding. A mobile stroke unit expedites treatment, using 'exception from informed consent' for urgent cases.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy